Login | Cell Therapy Hub

About us
Local Team
Resources
Account

CAR-T Academy
News & insights
Referring patients
Yescarta
Tecartus

You are about to visit CAR-T Tracker.

Please select your preferred language.

For the most recent version of the SmPC, please refer to the EMA website: Yescarta / Tecartus

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting schemes: www.famhp.be/en/side_effect (Belgium), https://guichet.public.lu/en/entreprises/sectoriel/sante/medecins/notification-effets-indesirables-medicaments.html (Grand Duchy of Luxembourg) Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via email: Safety_FC@gilead.com.

▼This medicinal product is subject to additional monitoring.

YESCARTA and TECARTUS are trademarks of Kite Pharma, Inc. GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc.

Website privacy statement english - french - dutch
Terms of use
Manage Cookie Settings

BE-TEC-0074 V2 - Date of preparation : December 2025